基于ASAS健康指数(U-ASAS-HI)的脊柱关节炎特异性健康效用反应性研究
本研究为ASAS-HI国际验证研究的辅助分析,纳入219例起始TNF抑制剂、csDMARD或NSAID的脊柱关节炎患者,评估U-ASAS-HI与通用效用(EQ-5D-5L、SF-6D)的反应性。结果显示U-ASAS-HI与外部锚定变化的相关性假设在75%比较中成立,其反应性与通用效用相似但并未更优。
要点
- U-ASAS-HI变化与外部健康锚定变化的相关性假设在75%比较中成立,EQ-5D-5L同样成立,SF-6D未成立。
- U-ASAS-HI的SRM和ES在TNFi组为大、csDMARD组为中、NSAID组为小到中等。
- U-ASAS-HI区分BASDAI-50%应答者与非应答者的能力与通用效用工具在ROC比较中无差异。
核心结论
- 在预期变化的情境下,脊柱关节炎特异性U-ASAS-HI与其他SpA特异性结局变化的相关性符合预期,反应性良好,与通用效用相似但并未更优。
研究设计与样本
- ASAS-HI国际验证研究的辅助分析,纳入219例起始TNF抑制剂(110例)、csDMARD(37例)或NSAID(72例)的脊柱关节炎患者。
- 平均(标准差)年龄37(13)岁,63%为男性。
- 检验基线至随访期间效用变化与外部健康锚定变化相关性的先验假设。
- 在各治疗组计算标准化反应均值(SRM)和Cohen效应量(ES)。
- 通过标准化变化估计和ROC分析评估效用变化区分BASDAI-50%应答者与非应答者的能力。
主要发现
- 变化评分相关性假设在U-ASAS-HI的75%比较中成立,EQ-5D-5L同样为75%,SF-6D未成立。
- U-ASAS-HI的SRM和ES在TNFi治疗组为大,在csDMARD组为中等,在NSAID组为小到中等。
- U-ASAS-HI相比EQ-5D和SF-6D具有更大SRM和ES的假设未能在三个治疗组中一致确认。
- 区分BASDAI-50%应答者与非应答者的能力在ROC比较中各效用工具间无差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess responsiveness of the spondyloarthritis (SpA)-specific universal health utility from the ASAS Health Index (U-ASAS-HI) compared with generic health utilities (EQ-5D-5L and SF-6D). METHODS: Data were used from patients with SpA participating in the ASAS-HI international validation study and starting TNF inhibitor (TNFi), conventional synthetic DMARD (csDMARD) or NSAID. A priori hypotheses on correlation of change in utility and change in external health anchors between baseline and follow-up were tested. Standardized response mean (SRM) and Cohen's effect size (ES) were calculated in each treatment group. The ability of changes in utilities to discriminate between BASDAI-50% (non)-responders was assessed by standardized estimate of change and receiver operating characteristic (ROC) analyses. RESULTS: 219 patients were included (110 TNFi, 37 csDMARD, and 72 NSAID). Mean (s.d.) age was 37 (13) years and 63% were male. Hypotheses on correlations of change scores were confirmed for 75% of comparisons for U-ASAS-HI and EQ-5D-5L, but not for SF-6D. As expected, SRM and ES for the U-ASAS-HI were large in the TNFi-treated group, moderate in the csDMARD group and small to moderate in the NSAID group. The hypothesized larger SRM and ES for U-ASAS-HI compared with EQ-5D and SF-6D could not be consistently confirmed across the three treatment groups. Ability to discriminate between BASDAI-50% responders and non-responders did not differ among utility instruments in ROC comparison. CONCLUSION: In a context where change is expected, the SpA-specific U-ASAS-HI correlates as expected with changes in other SpA-specific outcomes and shows good responsiveness, which is similar to but not better than for generic utilities.
引用
- Calixto OJ, Baraliakos X, Boonen A, et al. Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study. Rheumatology (Oxford). 2026. PMID: 41124607. doi:10.1093/rheumatology/keaf554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。